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Background: The activation of international, non-profit clinical trial funded by the EC
requires specific timelines according to the EU rules. This study describes all the
logistic procedures, difficulties and time spent for the activation of the ET-FES
TRANSCAN funded project in 4 EU countries.
Materials and methods: ET-FES study was funded by ERA-Net Transcan JTC 2011,
sponsored by EO Galliera (Genoa, Italy) and is conducted in Italy, Spain, France and
Germany. The primary objective is to validate the use of a new radiotracer 18F-FES
PET/CT, targeting estrogen receptors, as a tool to predict endocrine responsiveness in
advanced breast cancer. ET-FES was approved for funding from EU on 10/2012.
Results: The official start by the Italian Ministry of Health was set up on 06/2013 (8
mos after the expected/ foreseen date). Time to IRB approval was 1.5 mos in Italy, 2
mos in France and 3 mos in Spain and 13 mos in Germany. Time to Competent
authority (CA) approval (from EC submission): Italy 11 mos, Spain 16 mos, France 5
mos, Germany 14+. Overall, no ethical objection was raised by the different ECs; some
minor clinical and methodological issues were raised from the EC in Germany and
Spain. Issues from the CAs were raised in all countries, except France (12 queries in
Italy, 21 in Spain and 23 in Germany), on quality aspects of 18F-FES IMPD. At the
sponsor level, the time to the final agreement signature with the 18F-FES
manufacturing company required 13 mos. First patient in (Italy): 14 mos after EC
approval and 20 mos after the official start of the ET-FES project, as set up by the
Italian Ministry of Health.
Conclusions: From a regulatory aspect, taking into account that the ET-FES trial
involves an experimental drug (18F-FES), without MA in EU, the approval process was
timely completed at the EC level in Italy, France and Spain. Time to CA approval was
different in the various countries and was timely achieved only in France: this was due
to the different requirements from each local CA, indicating the absence of harmonized
procedures as requested by the 2001/20/EC directive. Finally, at the Italian level, the
critical issue concerns the administrative procedures to activate this type of EU
projects, requiring a suboptimal time span, in order to satisfy all the legal aspects on
contracts by public bodies, according to the Italian law. These timelines need to be
considered when applying for EU calls where the allowed project duration is 3 years.
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